Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR9281 in hypertension and impaired glucose tolerance
NCT00847899Phase 2Completed
- Sponsor
- Arete Therapeutics Inc.
- Start
- Jan 2009
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AR-9281 in hypertension (HTN), impaired glucose tolerance (IGT), sponsored by Arete Therapeutics Inc.. Started Jan 2009; status: completed.
02
Drugs
AR-9281
03
Conditions
hypertension (HTN)impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT00847899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00847899.